Immune evasion in Kaposi's sarcoma-associated herpes virus associated oncogenesis - PubMed (original) (raw)

Review

Immune evasion in Kaposi's sarcoma-associated herpes virus associated oncogenesis

Chengyu Liang et al. Semin Cancer Biol. 2008 Dec.

Abstract

A hallmark of herpesviruses is a lifelong persistent infection, which often leads to diseases upon immune suppression of infected host. Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), is etiologically linked to the development of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and Multicentric Castleman's disease (MCD). In order to establish a persistent infection, KSHV dedicates a large portion of its genomic information to sabotage almost every aspect of host immune system. Thus, understanding the interplay between KSHV and the host immune system is important in not only unraveling the complexities of viral persistence and pathogenesis, but also discovering novel therapeutic targets. This review summarizes current knowledge of host immune evasion strategies of KSHV and their contributions to KSHV-associated diseases.

PubMed Disclaimer

Figures

Fig. 1.

Schematic representation of KSHV immune evasion strategies.

Similar articles

• Immune evasion strategies of Kaposi's sarcoma-associated herpesvirus.
  Means RE, Choi JK, Nakamura H, Chung YH, Ishido S, Jung JU. Means RE, et al. Curr Top Microbiol Immunol. 2002;269:187-201. doi: 10.1007/978-3-642-59421-2_12. Curr Top Microbiol Immunol. 2002. PMID: 12224509 Review.
• Immune evasion by Kaposi's sarcoma-associated herpesvirus.
  Lee HR, Lee S, Chaudhary PM, Gill P, Jung JU. Lee HR, et al. Future Microbiol. 2010 Sep;5(9):1349-65. doi: 10.2217/fmb.10.105. Future Microbiol. 2010. PMID: 20860481 Free PMC article. Review.
• Immune evasion by Kaposi's sarcoma-associated herpesvirus.
  Coscoy L. Coscoy L. Nat Rev Immunol. 2007 May;7(5):391-401. doi: 10.1038/nri2076. Nat Rev Immunol. 2007. PMID: 17457345 Review.
• Kaposi's Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes.
  Host KM, Jacobs SR, West JA, Zhang Z, Costantini LM, Stopford CM, Dittmer DP, Damania B. Host KM, et al. mBio. 2017 Oct 10;8(5):e00917-17. doi: 10.1128/mBio.00917-17. mBio. 2017. PMID: 29018115 Free PMC article.
• Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
  Parravicini C, Chandran B, Corbellino M, Berti E, Paulli M, Moore PS, Chang Y. Parravicini C, et al. Am J Pathol. 2000 Mar;156(3):743-9. doi: 10.1016/S0002-9440(10)64940-1. Am J Pathol. 2000. PMID: 10702388 Free PMC article.

Cited by

• Clinical Efficacy of the HIV Protease Inhibitor Indinavir in Combination with Chemotherapy for Advanced Classic Kaposi Sarcoma Treatment: A Single-Arm, Phase II Trial in the Elderly.
  Sgadari C, Scoppio B, Picconi O, Tripiciano A, Gaiani FM, Francavilla V, Arancio A, Campagna M, Palladino C, Moretti S, Monini P, Brambilla L, Ensoli B. Sgadari C, et al. Cancer Res Commun. 2024 Aug 1;4(8):2112-2122. doi: 10.1158/2767-9764.CRC-24-0102. Cancer Res Commun. 2024. PMID: 39028943 Free PMC article. Clinical Trial.
• Identification of AIDS-Associated Kaposi Sarcoma: A Functional Genomics Approach.
  Zhang P, Wang J, Zhang X, Wang X, Jiang L, Gu X. Zhang P, et al. Front Genet. 2020 Jan 24;10:1376. doi: 10.3389/fgene.2019.01376. eCollection 2019. Front Genet. 2020. PMID: 32038721 Free PMC article.
• Identification of new antiviral agents against Kaposi's sarcoma-associated herpesvirus (KSHV) by high-throughput drug screening reveals the role of histamine-related signaling in promoting viral lytic reactivation.
  Chen J, Dai L, Goldstein A, Zhang H, Tang W, Forrest JC, Post SR, Chen X, Qin Z. Chen J, et al. PLoS Pathog. 2019 Dec 2;15(12):e1008156. doi: 10.1371/journal.ppat.1008156. eCollection 2019 Dec. PLoS Pathog. 2019. PMID: 31790497 Free PMC article.
• RING-Domain E3 Ligase-Mediated Host-Virus Interactions: Orchestrating Immune Responses by the Host and Antagonizing Immune Defense by Viruses.
  Zhang Y, Li LF, Munir M, Qiu HJ. Zhang Y, et al. Front Immunol. 2018 May 22;9:1083. doi: 10.3389/fimmu.2018.01083. eCollection 2018. Front Immunol. 2018. PMID: 29872431 Free PMC article. Review.
• KSHV strategies for host dsDNA sensing machinery.
  Gao H, Song Y, Liu C, Liang Q. Gao H, et al. Virol Sin. 2016 Dec;31(6):466-471. doi: 10.1007/s12250-016-3877-3. Epub 2016 Dec 5. Virol Sin. 2016. PMID: 27933565 Free PMC article. Review.

References

1. 1. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994;266:1865–9. - PubMed
2. 1. Ganem D KSHV infection and the pathogenesis of Kaposi’s sarcoma. Annu Rev Pathol 2006;1:273–96. - PubMed
3. 1. Schulz TF. Epidemiology of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8. Adv Cancer Res 1999;76:121–60. - PubMed
4. 1. Sarid R, Olsen SJ, Moore PS. Kaposi’s sarcoma-associated herpesvirus: epidemiology, virology, and molecular biology. Adv Virus Res 1999;52:139–232. - PubMed
5. 1. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332:1186–91. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central

• Medical

  • MedlinePlus Health Information